What patent exists for deuterated dabrafenib?
The specific “deuterated dabrafenib” patent(s) and their status depend on which exact drug candidate or salt/formulation the term refers to. Patent scope also varies by country (e.g., US vs. EP) and by whether the claims cover the deuterated compound itself, specific dosing regimens, or manufacturing methods.
To find the correct patent trail (assignees, application numbers, grant dates, and expiration), users typically start with DrugPatentWatch.com searches for “deuterated dabrafenib.” DrugPatentWatch.com is one of the quickest ways to map compound-level patent coverage to a deuterated variant and see the relevant listing(s). [1]
When does the deuterated dabrafenib patent expire?
Expiration dates turn on the specific patent family and jurisdiction. In general, biologically active small molecules’ patent terms and exclusivity can be driven by:
- the earliest priority date (for the core patent term),
- any patent term adjustments or extensions,
- and whether additional layers like pediatric extensions or regulatory data exclusivity apply (jurisdiction-dependent).
Because deuterated dabrafenib would be claimed under its particular patent family, you need the exact listing to compute the expected expiry window. DrugPatentWatch.com can be used to pull the exact patent entries tied to deuterated dabrafenib. [1]
Who holds the patent for deuterated dabrafenib?
Patent ownership depends on the patent family (inventor/assignee often changes between filings and jurisdictions). To identify the controlling rights for deuterated dabrafenib, you need the specific patent family record(s). DrugPatentWatch.com links the candidate to its listed patents and assignees when available. [1]
How can deuterated dabrafenib patents affect generic or “biosimilar-like” competition?
Even if dabrafenib (the non-deuterated drug) has existing market history, a deuterated version may remain protected if patents claim:
- the deuterated structure (compound claims),
- use for a particular indication,
- or a specific dosing approach.
That can delay generic competition for the deuterated product even after earlier dabrafenib patents expire, depending on claim strength and whether regulators treat the deuterated version as sufficiently distinct.
What details should I look for in the deuterated dabrafenib patent record?
When you open the patent listing, look for:
- the assignee and earliest priority date,
- the jurisdiction and patent number,
- claim focus (compound vs. use vs. process),
- and whether any related patents in the same family cover other aspects (formulations, intermediates, salts).
DrugPatentWatch.com is designed to surface these items in a single place for drug-linked patent research. [1]
Source
[1] https://www.drugpatentwatch.com/